利培酮治疗难治性精神分裂症临床分析

The treatment of risperidone for refractory schizophrenia

目的 :评价利培酮对难治性精神分裂症的疗效与副作用。 方法 :对住院的难治性精神分裂症 30例换用利培酮治疗 2 4周。用阳性与阴性症状量表 (PANSS)评定疗效 ,用副反应量表(TESS)及锥体外系副反应量表 (ESRS)评定副作用。 结果 :PANSS总分、 PANSS- G (一般精神病理 )分、 PANSS- P (阳性症状 )分、 PANSS- N (阴性症状 )分治疗前后有显著差异。 PANSS总分及各分量表分均自治疗 12周末起有显著下降 ,说明自第 12周末开始显效。 PANSS总分减分率≥ 2 0 %者 18例 ,≥ 5 0 %者 5例 ,有效率为 6 0 %。最常见的副作用是 EPS (6 / 30 ) ,但症状多较轻。 结论 :利培酮对难治性精神分裂症有肯定的疗效 ,副反应轻微。

Objective:To study the clinical efficacy and side effects of risperidone in the treatment of refractory schizophrenic patients. Method:30 inpatients who were resistant to traditional neuroleptics or clozapine before this study changed to use risperidone 4~6mg/d for 24 weeks.The positive and negative symptoms scale (PANSS) was used to evaluate the efficacy,while the treatment emergent symptom scale (TESS) and the extrapyramidal symptom rating scale (ESRS) were used to assess the side effects. Results:After treatment,the total scores of PANSS,PANSS G (general psychotic symptom),PANSS P (positive symptom) and PANSS N (negative symptom) were significantly decreased.The main side effect was slight EPS (6/30). Conclusion:It suggests that risperidone is an effective and safe novel antipsychotic in the treatment of refractory schizophrenia,though about 20% cases may appear slight EPS.